| Sarcoma |
2016-005252-21: Increasing the amount of pazopanib in the blood by splitting intake moments Verhogen van de hoeveelheid pazopanib in het bloed door het spreiden van inname momenten |
|
|
| Ongoing | 4 | 10 | Europe | Tablet, Votrient | Netherlands Cancer Institute, Netherlands Cancer Institute | Patients for whom pazopanib is considered standard care (advanced renal cell carcinoma and advanced soft-tissue sarcoma). Patiënten voor wie behandeling met pazopanib standaard zorg is (gevorderd renaal cel carcinoom of gevorderd weke delen sarcoom)., Patients with advanced renal cell carcinoma or advanced soft-tissue sarcoma Patiënten met nierkanker of weke delen kanker, Diseases [C] - Cancer [C04] | | | | |
2020-005751-21: Clinical Trial Extension Study with Avapritinib for Patients with Gastrointestinal Stromal Tumors |
|
|
| Not yet recruiting | 4 | 5 | Europe | Avapritinib, BLU-285, Tablet | Blueprint Medicines, Blueprint Medicines | Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST), Gastrointestinal Tumours, Diseases [C] - Cancer [C04] | | | | |
| Completed | 4 | 57 | Europe, Canada, US, RoW | Nilotinib, AMN107 | Novartis Pharmaceuticals | Chronic Myelogenous Leukemia (CML), Metastatic Gastrointestinal Stromal Tumors (GIST), Acute Lymphoblastic Leukemia (ALL), Receptor Tyrosine Kinase (KIT) Mutated Melanoma | 07/23 | 07/23 | | |
NCT04033081: Registry of Sarcoma Patients Treated With Permanently Implantable LDR CivaSheet® |
|
|
| Recruiting | 4 | 100 | US | CivaSheet, brachytherapy, Intraoperative Radiation Therapy | CivaTech Oncology, TAB Clinical | Sarcoma | 12/24 | 12/28 | | |
| Active, not recruiting | 4 | 34 | Europe | Nilotinib | Novartis Pharmaceuticals | Gastrointestinal Stromal Tumors | 12/24 | 12/24 | | |
NCT04825574: Study for Patients Previously Treated in Avapritinib Clinical Trials |
|
|
| Active, not recruiting | 4 | 5 | Europe | Avapritinib, BLU-285 | Blueprint Medicines Corporation | Gastrointestinal Stromal Tumors | 08/25 | 08/25 | | |
NCT01742299 / 2012-002540-25: Study to Allow Access to Imatinib for Patients Who Are on Imatinib Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator |
|
|
| Active, not recruiting | 4 | 155 | Europe, US, RoW | imatinib mesylate, STI571 | Novartis Pharmaceuticals | GIST and CML | 04/33 | 04/33 | | |
2020-004780-71: A study using a hormone drug during chemotherapy for fertility protection of young women and teenagers with cancer - ProFertil En studie med ett hormonpreparat som utvärderar effekten av fertilitet hos unga kvinnor och tonåringar med cancer - ProFertil |
|
|
| Not yet recruiting | 3 | 500 | Europe | Pamorelin, Powder and solvent for prolonged-release suspension for injection, Pamorelin | Karolinska University Hospital, Karolinska University Hospital | Breast CancerAcute LeukemiaLymphomas (Hodgkin and non-Hodgkin)Sarcomas (Osteo, Soft tissue and Ewing) Bröstcancer, Akut Leukemi, Lymfom (Hodgkin och non-Hodgkin), Sarkom (Ben, Mjukvävnad och Ewing), Breast CancerBlood CancerCancer in lymphnodesCancer in bones Bröstcancer, Blodcancer, Cancer i lymfkörtlar, Cancer i skelett, Diseases [C] - Cancer [C04] | | | | |
NCT00707109: Trabectedin for Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma |
|
|
| Recruiting | 3 | 1200 | US | trabectedin, Yondelis | University of Medicine and Dentistry New Jersey, Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Sarcoma | 12/09 | | | |
| Active, not recruiting | 3 | 318 | Europe | cisplatin, doxorubicin hydrochloride, etoposide, ifosfamide, methotrexate, zoledronic acid, conventional surgery | UNICANCER, Novartis, Chugai Pharmaceutical, National Cancer Institute, France, SFCE, Ligue contre le cancer, France | Sarcoma | 12/15 | 12/26 | | |
NCT01933932 / 2013-001676-38: Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC |
|
|
| Active, not recruiting | 3 | 510 | Europe, Canada, US, RoW | Selumetinib, AZD6244; ARRY-142886, Docetaxel, Placebo, Pegylated G-CSF, Pegfilgrastim 6 mg | AstraZeneca | Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV | 06/16 | 12/24 | | |
|
|
|
2016-003214-27: Clinical trial to evaluate blood loss by administering transexamic acid via topical, intravenous, or both in surgically operated patients with osteous or soft tissue sarcomas. Ensayo clÃnico para evaluar la pérdida de sangre administrando ácido transexámico via tópica, intravenosa u ambas en pacientes intervenidos quirúrgicamente de sarcomas oseos o de partes blandas |
|
|
| Ongoing | 3 | 150 | Europe | Amchafibrin, 53939, Concentrate and solvent for solution for injection, Concentrate for dip solution, Amchafibrin | Irene Barrientos Ruiz, Fundacion SECOT | Oncological orthopedic surgery (bone and soft tissue sarcomas in the appendicular skeleton, pelvis and scapular girdle). cirugÃa ortopédica oncológica (sarcomas óseos y de partes blandas en esqueleto apendicular, pelvis y cintura escapular)., Bone or soft tissue cancer Bone or soft tissue cancer, Diseases [C] - Cancer [C04] | | | | |
| Active, not recruiting | 3 | 509 | Europe, Canada, Japan, US, RoW | Olaratumab, LY3012207, Doxorubicin, Placebo | Eli Lilly and Company | Soft Tissue Sarcoma | 12/18 | 07/24 | | |
2017-002851-27: GENETIC SEQUENCING FOR THE TREATMENT OF ADVANCED SOFT-TISSUE SARCOMAS SEQUENCAGE GENETIQUE POUR LE TRAITEMENT DES SARCOMES DES TISSUS MOUS |
|
|
| Not yet recruiting | 3 | 960 | Europe | CAPMATINIB, OLAPARIB, DURVALUMAB, GLASDEGIB, TAS-120, INC280, AZD2281, MEDI4736, PF-04449913, TAS-120, Capsule, hard, Film-coated tablet, Concentrate for solution for infusion, Tablet, TASIGNA, ZYKADIA, TYVERB, MEKINIST, TAFINLAR, LYNPARZA, IBRANCE | INSERM, Institut National du Cancer (INCa) | Adult patients with locally advanced/unresectable and/or metastatic soft-tissue sarcoma, Adult patients with advanced soft-tissue sarcoma, Diseases [C] - Cancer [C04] | | | | |
2019-003014-13: Interest of peri operative CHemotherapy In patients with CINSARC high-risk localized grade 1 or 2 Soft Tissue Sarcoma. Intérêt de la chimiothérapie péri-opératoire chez les patients porteurs de sarcomes des tissus mous localisés de grade 1 ou 2, définis à HAUT RISQUE par la signature CINSARC. |
|
|
| Not yet recruiting | 3 | 600 | Europe | DOXORUBICIN, IFOSFAMIDE, DACARBAZINE, Solution for infusion, Powder for solution for injection, Powder for solution for infusion | INSTITUT CLAUDIUS REGAUD, Direction Générale de l’Offre de Soins (DGOS) | Soft Tissue Sarcoma Sarcome des tissus mous, Soft Tissue Sarcoma Sarcome des tissus mous, Diseases [C] - Cancer [C04] | | | | |
2019-003543-30: A study to test the effect of chemotherapy before surgery compared to surgery alone in patients with high risk retroperitoneal sarcoma |
|
|
| Ongoing | 3 | 250 | Europe | Doxorubicin, Epirubicin, Dacarbazin, Ifosfamide, [Doxorubicin], [Epirubicin], [Dacarbazin], [Ifosfamide], Solution for infusion, Solution for injection/infusion, Powder for solution for injection/infusion | European Organisation for Research and Treatment of Cancer, EORTC AISBL/IVZW, European Organisation for the Research and Treatment of Cancer, Anticancer fund | Primary high risk leiomyosarcoma or Liposarcoma of retroperitoneal space or infra-peritoneal spaces of pelvis, Retroperitoneal sarcoma: a sarcoma developed in the back of the belly, next to the kidneys, in a relatively “hidden” location known as the retroperitoneum., Diseases [C] - Cancer [C04] | | | | |
| Active, not recruiting | 3 | 453 | Europe, Canada, US, RoW | Ripretinib, DCC-2618, Sunitinib, Sutent | Deciphera Pharmaceuticals LLC | Gastrointestinal Stromal Tumors | 09/21 | 12/24 | | |
| Active, not recruiting | 3 | 120 | Europe, US | Crenolanib, Crenolanib Besylate, Placebo | Arog Pharmaceuticals, Inc., Centre Leon Berard, Fox Chase Cancer Center | GIST With D842V Mutated PDGFRA Gene | 08/21 | 08/21 | | |
2020-005858-21: tTF-NGR Randomized Study - STS tTF-NGR randomisierte Studie - STS |
|
|
| Not yet recruiting | 3 | 126 | Europe | tTF-NGR, Yondelis, ET-743, Solution for infusion in pre-filled syringe, Powder for concentrate for solution for infusion, Yondelis | Westfälische Wilhelms-Universität Münster c/o Universitätsklinikum Münster, Geschäftsbereich Recht u. Drittmittel, ANTUREC Pharmaceuticals GmbH | Patients (18-75 years) with metastatic and/or refractory soft-tissue sarcoma after failure of anthracycline-containing 1st line therapy or with contraindications to anthracyclines (CD13 positivity: grade >/= 1+)., Patients with metastatic and/or refractory soft-tissue sarcoma after failure of anthracycline-containing first line therapy or with contraindications to these drugs., Diseases [C] - Cancer [C04] | | | | |
NCT03495921: A Trial For Participants With Ewing's Sarcoma Treated With Vigil in Combination With Irinotecan and Temozolomide |
|
|
| Terminated | 3 | 32 | US | Vigil, Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy, FANG vaccine, Irinotecan, Camptosar, Camptothecin-11, CPT-11, Temozolomide, Temodar | Gradalis, Inc. | Ewing Sarcoma, Ewing Family of Tumors, Ewing's Tumor Metastatic, Ewing's Sarcoma Metastatic, Ewing's Tumor Recurrent, Rare Diseases, Sarcoma, Neoplasms, Connective and Soft Tissue, Neoplasms by Histologic Type, Neoplasms, Bone Tissue, Neoplasms, Connective Tissue, Sarcoma, Ewing, Neoplasms | 01/22 | 01/22 | | |
| Active, not recruiting | 3 | 142 | Europe, Canada, US | Nirogacestat oral tablet, PF-03084014, Placebo Oral Tablet | SpringWorks Therapeutics, Inc. | Desmoid Tumor, Aggressive Fibromatosis | 04/22 | 12/24 | | |
|
2021-000125-27: TOLERANCE: a clinical trial on more tolerable treatments for elderly patients with advanced soft tissue sarcoma TOLERANCE: uno studio clinico su trattamenti più tollerabili per pazienti anziani con sarcoma dei tessuti molli avanzato |
|
|
| Ongoing | 3 | 185 | Europe, RoW | Doxorubicin, Cyclophosphamide, Prednisolone, [Doxorubicin], [Cyclophosphamide], [Prednisolone], Solution for injection/infusion, Coated tablet, Tablet | EORTC AISBL/IVZW, European Organisation for Research and Treatment of Cancer (EORTC), European Organisation for Research and Treatment of Cancer (EORTC), Fonds Cancer (FOCA), Rising Tide Foundation | Advanced/metastatic soft tissue sarcoma Sarcoma avanzato/metastatico dei tessuti molli, Sarcoma Sarcoma, Diseases [C] - Cancer [C04] | | | | |
NCT04359550: Study of ZKAB001 for Maintenance Therapy in Patients With High-grade Osteosarcoma After Adjuvant Chemotherapy |
|
|
| Not yet recruiting | 3 | 362 | NA | Recombinant human anti-PD-L1 monoclonal antibody (ZKAB001), placebo | Lee's Pharmaceutical Limited | High-grade Osteosarcoma | 06/22 | 06/23 | | |
MANTRA, NCT04979442: Treatment of Milademetan Versus Trabectedin in Patient With Dedifferentiated Liposarcoma |
|
|
| Terminated | 3 | 175 | Europe, Canada, US, RoW | RAIN-32, Milademetan, Trabectedin, Yondelis | Rain Oncology Inc | Dedifferentiated Liposarcoma | 10/23 | 10/23 | | |
2021-001394-23: Clinical study comparing Milademetan Versus Trabectedin in Patients with Dedifferentiated Liposarcoma |
|
|
| Not yet recruiting | 3 | 160 | Europe | Milademetan, Trabectedin, DS-3032b, Capsule, Powder for concentrate for solution for infusion | Rain Therapeutics, Inc., Rain Oncology Inc., Rain Therapeuthic Inc, RAIN Therapeutics Inc. | Dedifferentiated liposarcoma, Liposarcoma, Diseases [C] - Cancer [C04] | | | | |
| Active, not recruiting | 3 | 325 | Europe, US, RoW | AL3818, Catequentenib, Anlotinib, Dacarbazine, DTIC, AL3818 or placebo | Advenchen Laboratories, LLC | Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma, Soft-Tissue Sarcoma | 12/24 | 06/25 | | |
NCT04409223: Efficacy and Safety of Famitinib Versus Sunitinib in the Treatment of Advanced Gastrointestinal Stromal Tumour Patients After Failure of Imatinib |
|
|
| Terminated | 3 | 185 | RoW | Famitinib capsules, Sunitinib Capsules, Sutent | Jiangsu HengRui Medicine Co., Ltd. | Gastrointestinal Stromal Tumors | 03/22 | 03/22 | | |
| Recruiting | 3 | 102 | Europe | Onfekafusp alfa, L19TNF, Doxorubicin | Philogen S.p.A. | Soft Tissue Sarcoma | 12/25 | 12/25 | | |
SARC041, NCT04967521: Study of Abemaciclib Versus Placebo in Patients With Advanced Dedifferentiated Liposarcoma |
|
|
| Recruiting | 3 | 108 | US | Abemaciclib, LY2835219, Placebo | Sarcoma Alliance for Research through Collaboration, Eli Lilly and Company | Advanced Dedifferentiated Liposarcoma | 05/24 | 11/24 | | |
| Not yet recruiting | 3 | 717 | Europe | Tislelizumab, Blood sampling, Placebo | Gustave Roussy, Cancer Campus, Grand Paris, BeiGene, C2i Genomics | Cancer, Lung Cancer, Colo-rectal Cancer, Pancreas Cancer, Soft Tissue Sarcoma | 05/28 | 04/29 | | |
NCT05121350: A Clinical Trial to Evaluate the Efficacy and Safety of Anotinib Hydrochloride Capsule Combined With Epirubicin Hydrochloride Versus Placebo Combined With Epirubicin Hydrochloride in First-line Treatment of Advanced Soft Tissue Sarcoma |
|
|
| Recruiting | 3 | 256 | RoW | Anlotinib hydrochloride capsule, Epirubicin, Arotinib hydrochloride capsule placebo | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Soft Tissue Sarcoma | 06/24 | 06/24 | | |
INVINCIBLE-3, NCT06263231: A Study to Investigate Efficacy & Safety of INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas |
|
|
| Recruiting | 3 | 333 | US | INT230-6, Eribulin, Trabectedin, Pazopanib | Intensity Therapeutics, Inc., Premier Research Group plc | Sarcoma,Soft Tissue | 12/27 | 12/28 | | |
CHONQUER, NCT06127407: Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen |
|
|
| Not yet recruiting | 3 | 136 | NA | Ivosidenib 500mg, Placebo | Servier Bio-Innovation LLC, Institut de Recherches Internationales Servier | Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen | 12/26 | 04/31 | | |
NCT06370871: Brightline-3: A Study to Find Out Whether Brigimadlin in Combination With Ezabenlimab Helps People With Advanced Soft Tissue Sarcoma |
|
|
| Not yet recruiting | 3 | 263 | NA | Brigimadlin, BI 907828, Ezabenlimab, BI 754091, Gemcitabine, Docetaxel | Boehringer Ingelheim | Advanced Soft Tissue Sarcoma, Undifferentiated Pleomorphic Sarcoma (UPS), Myxofibrosarcoma (MFS) | 07/26 | 10/28 | | |
CIRSARC, NCT03805022: Benefit of Intensified Peri-operative Chemotherapy Within High-risk CINSARC Patients With Resectable Soft-tissue Sarcomas |
|
|
| Recruiting | 3 | 351 | Europe | Doxorubicin, Ifosfamide or dacarbazine, At the discretion of the investigator | Institut Bergonié, Novartis, Chugai Pharma France | Non-metastatic Soft-tissue Sarcoma, Resectable | 02/25 | 02/25 | | |
| Active, not recruiting | 3 | 160 | Europe, Japan, US, RoW | Sotorasib, AMG 510, Lumakras, Lumykras, Panitumumab, Vectibix, Trifluridine and Tipiracil, Lonsurf, Regorafenib, Stivarga | Amgen | Colorectal Cancer (CRC) | 03/25 | 03/25 | | |
|
PEAK, NCT05208047: (Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors |
|
|
| Recruiting | 3 | 426 | Europe, Canada, US, RoW | CGT9486 plus sunitinib, CGT9486, Sunitinib, sunitinib - Part 1b, sunitinib - Part 2 | Cogent Biosciences, Inc. | Advanced Gastrointestinal Stromal Tumors, Metastatic Cancer | 07/25 | 09/26 | | |
Brightline-4, NCT06058793: A Study to Test How Well Brigimadlin is Tolerated by People With a Type of Cancer Called Dedifferentiated Liposarcoma |
|
|
| Recruiting | 3 | 240 | Europe, Canada, Japan, US, RoW | Brigimadlin, BI 907828 | Boehringer Ingelheim | Liposarcoma, Dedifferentiated | 11/25 | 11/25 | | |
INSIGHT, NCT05734105: A Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib |
|
|
| Recruiting | 3 | 54 | Europe, Canada, US, RoW | Ripretinib, QINLOCK, DCC-2618, Sunitinib, Sutent | Deciphera Pharmaceuticals LLC | GIST | 02/26 | 12/27 | | |
FUS-ALS, NCT04768972 / 2020-005522-28: FUSION: A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ION363 in Amyotrophic Lateral Sclerosis Participants With Fused in Sarcoma Mutations |
|
|
| Recruiting | 3 | 95 | Europe, Canada, US, RoW | ION363, Placebo | Ionis Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc. | Amyotrophic Lateral Sclerosis | 06/26 | 03/28 | | |
ARGSARC, NCT05712694: Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma |
|
|
| Recruiting | 3 | 300 | Canada, US, RoW | ADI PEG20, Pegargiminase, Placebo | Polaris Group | Soft Tissue Sarcoma | 12/27 | 12/27 | | |
| Recruiting | 3 | 164 | Europe, Canada, US, RoW | Tazemetostat, EPZ-6438, IPN60200, Doxorubicin HCl, Tazverik®, Placebo | Epizyme, Inc. | Advanced Soft-tissue Sarcoma, Advanced Epithelioid Sarcoma | 01/29 | 01/30 | | |
|
2014-000259-99: A comparison of four widely used chemotherapy regimens for the treatment of Ewing sarcoma, a type of bone cancer, to see which is most effective and/or has the fewest side effects. |
|
|
| Ongoing | 2/3 | 400 | Europe | Cyclophosphamide, Topotecan, Irinotecan, Temozolomide, Gemcitabine, Docetaxel, Ifosfamide, Cyclophosphamide, Topotecan, Irinotecan, Temozolomide, Gemcitabine, Docetaxel, Ifosfamide, Infusion, Capsule, hard, , Cyclophosphamide, HYCAMTIN, CAMPTO, Temodal, GEMZAR, TAXOTERE, Ifosfamide | University of Birmingham, UNIVERSITY OF BIRMINGHAM, European Commission, German Cancer Aid | Recurrent and refractory Ewing sarcoma, Ewing sarcoma, a type of bone cancer, that has either grown during initial treatment or has grown after the end of treatment., Diseases [C] - Cancer [C04] | | | | |
2022-000073-12: A PHASE 2/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF UNESBULIN IN UNRESECTABLE OR METASTATIC, RELAPSED OR REFRACTORY LEIOMYOSARCOMA |
|
|
| Ongoing | 2/3 | 345 | Europe | unesbulin, DTIC, PTC596, Tablet, Powder for solution for injection/infusion | PTC Therapeutics, Inc., PTC THERAPEUTICS INC., PTC Therapeutics, Inc. | Leiomyosarcoma, Soft Tissue Sarcoma, Diseases [C] - Cancer [C04] | | | | |
| Active, not recruiting | 2/3 | 400 | Europe, Canada, Japan, US, RoW | Brigimadlin (BI 907828), Brigimadlin, Doxorubicin | Boehringer Ingelheim | Liposarcoma, Dedifferentiated | 04/24 | 05/26 | | |
| Active, not recruiting | 2/3 | 360 | Europe, Canada, US, RoW | Unesbulin, PTC596, Dacarbazine, DTIC, Placebo | PTC Therapeutics | Leiomyosarcoma | 06/24 | 06/24 | | |
| Active, not recruiting | 2/3 | 196 | Europe | Niraparib, Niraparib + TSR-042 (Dostarlimab), Chemotherapy Drugs | ARCAGY/ GINECO GROUP, Tesaro, Inc. | Ovarian Carcinosarcoma, Endometrial Carcinosarcoma | 12/24 | 06/25 | | |
|
| Active, not recruiting | 2/3 | 192 | Europe, US, RoW | AL102, Placebo | Ayala Pharmaceuticals, Inc, | Desmoid, Desmoid Tumor | 01/25 | 02/25 | | |
NCT06088290: Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma |
|
|
| Recruiting | 2/3 | 360 | Europe, US | Lurbinectedin, Doxorubicin | PharmaMar | Leiomyosarcoma | 11/26 | 11/26 | | |
NCT05755113: A Clinical Study to Investigate the Efficacy of Intratumoral Tigilanol Tiglate in Soft Tissue Sarcoma |
|
|
| Recruiting | 2a | 10 | US | Tigilanol Tiglate, EBC-46 | QBiotics Group Limited | Soft Tissue Sarcoma | 07/24 | 03/25 | | |
| Active, not recruiting | 2 | 20 | Japan | Tecentriq (atezolizumab) - Roche | National Cancer Center Hospital, Chugai Pharmaceutical Co., Ltd. | Unresectable alveolar soft tissue sarcoma | | | | |
2015-000087-34: Clinical trial comparing Lipegfilgrastim to Filgrastim in Pediatric Patients Diagnosed with Ewing Family of Tumors or Rhabdomyosarcoma Receiving Chemotherapy. Vizsgálat a lipegfilgrastim kezelés összehasonlítására a filgrastim kezeléssel, Ewing tumorok családjába tartozó betegséggel, vagy rhabdomioszarkómával diagnosztizált és kemoterápiával kezelt gyermek betegekben |
|
|
| Ongoing | 2 | 42 | Europe, RoW | Lipegfilgrastim, Neupogen, XM22, Solution for injection, LONQUEX, Neupogen 30 MU (0.3 mg/ml) solution for injection | Merckle GmbH, Merckle GmbH | Neutropenia in pediatric patients diagnosed with Ewing family of Tumors or rhabdomyosarcoma receiving chemotherapy Neutropénia Ewing tumorok családjába tartozó betegséggel, vagy rhabdomioszarkómával diagnosztizált és kemoterápiával kezelt gyermek betegekben, treatment of chemotherapy induced neutropenia (white blood cell decrease) a kemoterápia okozta neutropenia (a fehérvérsejtek csökkenése), Diseases [C] - Blood and lymphatic diseases [C15] | | | | |
2015-001298-42: A randomised phase II trial of imatinib alternating with regorafenib compared to imatinib alone for the first line treatment of advanced gastrointestinal stromal tumour (GIST) |
|
|
| Ongoing | 2 | 240 | Europe, RoW | Imatinib, Regorafenib, Tablet, Stivarga | European Organisation for Research and Treatment of Cancer, European Organisation for Research and Treatment of Cancer (EORTC), EORTC AISBL/IVZW, Bayer, AGITG, EORTC | unresectable metastatic GIST, gastrointestinal stromal tumour (GIST -, a cancer of the stomach and bowel) that has spread and cannot be surgically removed, Diseases [C] - Cancer [C04] | | | | |
NCT01814813: Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery |
|
|
| Terminated | 2 | 90 | US | HSPPC-96, bevacizumab | Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Agenus Inc. | Recurrent Glioblastoma, Recurrent Adult Brain Tumor, Gliosarcoma | 04/17 | 05/23 | | |
|
2016-004617-28: Does cediranib together with paclitaxel chemotherapy, or cediranib and olaparib, treat advanced endometrial cancer better than paclitaxel chemotherapy? |
|
|
| Not yet recruiting | 2 | 129 | Europe | Olaparib (Lynparza), Cediranib, Paclitaxel, AZD2281, AZD2171, Film-coated tablet, Concentrate for solution for infusion, Olaparib (Lynparza) | The University of Manchester, AstraZeneca Ltd | Advanced or recurrent endometrial carcinoma or carcinosarcoma, Endometrial cancer, Diseases [C] - Cancer [C04] | | | | |
| Completed | 2 | 582 | Europe | Crizotinib (PF-02341066) | European Organisation for Research and Treatment of Cancer - EORTC, Pfizer | Locally Advanced and/or Metastatic Anaplastic Large Cell Lymphoma, Locally Advanced and/or Metastatic Inflammatory Myofibroblastic Tumor, Locally Advanced and/or Metastatic Papillary Renal Cell Carcinoma Type 1, Locally Advanced and/or Metastatic Alveolar Soft Part Sarcoma, Locally Advanced and/or Metastatic Clear Cell Sarcoma, Locally Advanced and/or Metastatic Alveolar Rhabdomyosarcoma | 12/17 | 10/22 | | |
|
|
NCT02636725: Axitinib and Pembrolizumab in Subjects With Advanced Alveolar Soft Part Sarcoma and Other Soft Tissue Sarcomas |
|
|
| Completed | 2 | 33 | US | Axitinib, Inlyta, Pembrolizumab, MK-3475, Keytruda | Jonathan Trent, MD, PhD, Merck Sharp & Dohme LLC, Pfizer | Alveolar Soft Part Sarcoma, Soft Tissue Sarcomas | 05/18 | 03/23 | | |
2016-000065-23: DICE: An international study to assess the effectiveness of TAK228 in combination with weekly paclitaxel, compared with weekly paclitaxel on its own, in women with advanced/recurrent ovarian, fallopian tube or primary peritoneal cancer that is resistant to platinum-based chemotherapy |
|
|
| Not yet recruiting | 2 | 126 | Europe | Paclitaxel, TAK228, N/A, Concentrate for solution for infusion, Capsule | Imperial College London, Takeda Pharmaceuticals International Co. | Ovarian, fallopian tube or primary peritoneal cancer of clear cell, endometrioid or high grade serous subtype or carcinosarcoma, Ovarian Cancer, Diseases [C] - Cancer [C04] | | | | |
2018-001124-20: Efficacy of Olaratumab and Re-Treatment with Doxorubicin in anthracycline pretreated, advanced soft tissue sarcoma patients. |
|
|
| Ongoing | 2 | 60 | Europe | Dexrazoxan, Doxorubicinhydrochlorid, Concentrate for solution for infusion, Powder for solution for infusion, Lartruvo®, CARDIOXANE® | IKF Klinische Krebsforschung GmbH am Krankenhaus Nordwest, Lilly Deutschland GmbH, Clinigen Healthcare Limited | locally advanced (unresectable) or metastatic soft tissue sarcoma, locally advanced (unresectable) or metastatic soft tissue sarcoma, Diseases [C] - Cancer [C04] | | | | |
NCT02249949: Efatutazone Dihydrochloride in Treating Patients With Previously Treated Myxoid Liposarcoma That Cannot Be Removed by Surgery |
|
|
| Completed | 2 | 15 | US | efatutazone | Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Daiichi Sankyo, Inc. | Liposarcoma | 10/18 | 05/23 | | |
2018-003998-96: A Phase II, single arm Study of avelumab In combination with Axitinib in Patients With unresectable/metastatic Gastrointestinal Stromal Tumor after failure of standard therapy - AXAGIST |
|
|
| Not yet recruiting | 2 | 58 | Europe | Axitinib, AVELUMAB, [63539-026], [EU/1/17/1214/001], Coated tablet, Concentrate for solution for infusion, Inlyta, Bavencio | Centrum Onkologii – Instytut im. Marii Skłodowskiej - Curie, Maria Sklodowska-Curie National Research Institute of Oncology (MSCNRIO), Centrum Onkologii – Instytut im. Marii Skłodowskiej – Curie, Pfizer Polska, Maria Sklodowska-Curie National Research Istitute of Oncology, Pfizer Ltd | GIST - unresectable/metastatic Gastrointestinal Stromal Tumor after failure of standard therapy, Gastrointestinal Stromal Tumor (GIST), Diseases [C] - Cancer [C04] | | | | |
2018-004571-12: Trial in advanced Solitary Fibrous Tumor (SFT) Studio clinico nel Tumore Fibroso Solitario (TFS) |
|
|
| Not yet recruiting | 2 | 20 | Europe | Eribulina, [30058], Solution for injection, HALAVEN - 0.44MG/ML - SOLUZIONE INIETTABILE - USO ENDOVENOSO - FLACONCINO(VETRO) 2ML 6 FLACONCINI | ITALIAN SARCOMA GROUP, Eisai Italy | Advanced Solitary Fibrous Tumor (SFT) Tumore Fibroso Solitario in fase avanzata, Advanced Solitary Fibrous Tumor (SFT) Tumore Fibroso Solitario in fase avanzata, Diseases [C] - Cancer [C04] | | | | |
2018-001360-39: Randomized Controlled Trial comparing two groups of Patients with High-Risk, Localized Soft Tissue Sarcoma of the Extremity: the first one receiving Neoadjuvant Pembrolizumab with Radiotherapy and Adjuvant Pembrolizumab after surgery, and the second one receiving Radiotherapy and surgery, aiming to assess the safety and efficacy profile of Pembrolizumab Studio clinico controllato randomizzato che confronta due gruppi di pazienti affetti da sarcoma dei tessuti molli in fase localizzata, ad alto rischio: il primo riceve Pembrolizumab neoadiuvante abbinato a radioterapia e Pembrolizumab adiuvante dopo chirurgia, mentre il secondo riceve il trattamento standard: radioterapia preoperatoria e chirurgia. Lo scopo è di valutare sicurezza ed efficacia di Pembrolizumab. |
|
|
| Not yet recruiting | 2 | 110 | Europe | Pembrolizumab, [MK-3475], Solution for infusion | SARC, SARC, Merck Sharp & Dohme Corp. | This trial investigates whether neoadjuvant radiotherapy combined with pembrolizumab followed by surgical resection and adjuvant pembrolizumab improves disease-free survival for patients with high-risk soft tissue sarcoma of the extremity (undifferentiated pleomorphic sarcoma or dedifferentiated/pleomorphic liposarcoma, tumor size > 5 cm, grade 2 or 3 out of 3) compared to radiotherapy alone followed by surgical resection Lo studio indaga se la radioterapia neoadiuvante abbinata a pembrolizumab seguita da exeresi chirurgica e in seguito da pembrolizumab adiuvante migliori la sopravvivenza libera da malattia dei pazienti con sarcoma dei tessuti molli degli arti ad alto rischio (sarcoma pleomorfo indifferenziato o liposarcoma pleomorfo/dedifferenziato, dimensioni > 5 cm, grado 2 o 3 su 3) rispetto a sola radioterapia seguita da chirurgia., This trial investigates whether pre and post surgery pembrolizumab treatment improves disease-free survival for patients with high-risk soft tissue sarcoma of extremity vs RT alone followed by surgery Indaga se il trattamento con pembrolizumab pre e post chirurgia migliora sopravvivenza libera da malattia dei pazienti con sarcoma tessuti molli degli arti ad alto rischio rispetto a RT più chirurgia., Diseases [C] - Musculoskeletal Diseases [C05] | | | | |
2017-004239-35: Randomized Phase II, 2-arm Study of Immunomodulation with Atezolizumab concomitant with High Dose Radiation (SBRT) Versus SBRT Alone in Patients with Oligometastatic Sarcomas ETUDE DE PHASE II, RANDOMISEE EVALUANT L’IMMUNOTHERAPIE APRES HAUTE DOSE D’IRRADIATION (SBRT) VERSUS SBRT SEULE CHEZ LES PATIENTS PORTEURS DE SARCOMES OLIGOMETASTATIQUES |
|
|
| Not yet recruiting | 2 | 103 | Europe | atezolizumab, RO5541267, Concentrate for solution for infusion, Tecentriq | Centre Antoine Lacassagne, Institut National du Cancer, Roche SAS | Soft tissue sarcoma Sarcomes des tissus mous, Soft tissue sarcoma Sarcomes des tissus mous, Diseases [C] - Cancer [C04] | | | | |
2018-003779-36: ATr inhibitor in combination with olaparib in gynaecological cancers with ARId1A loss or no loss. |
|
|
| Not yet recruiting | 2 | 116 | Europe | AZD6738, Olaparib (Lynparza), AZD6738, Olaparib (AZD2281), Film-coated tablet, Olaparib (Lynparza) | The Institute of Cancer Research, AstraZeneca UK Limited, Lady Garden Foundation | Relapsed ovarian and endometrial clear cell carcinoma or relapsed other gynaecological cancers (endometriod (ovarian and endometrial), carcinosarcoma (ovarian and endometrial), cerviacal carcinoma (squamous and adenocarcinoma), Relapsed gynaecological cancers of rare subtypes, including clear cell (ovarian/uterus) and carcinosarcoma, cervical and endometrioid type., Diseases [C] - Cancer [C04] | | | | |
2019-001316-38: A clinical trial on an individualized treatment strategy for patients with metastatic non-clear cell kidney cancer Et lægemiddelforsøg af en individualiseret behandlingsstrategi til patienter med undertypen non-clear celle nyrekræft, som har spredt sig |
|
|
| Not yet recruiting | 2 | 30 | Europe | Capsule, hard, Film-coated tablet, Powder for concentrate for solution for infusion, Concentrate for solution for infusion, Tafinlar, Tarceva, Keytruda, Mekinist, Alecensa, Lynparza, Kadcyla, Cabometyx, Xalkori, Ibrance, Tagrisso, Glivec, Sutent, Opdivo | Department of Oncology, Herlev University Hospital, Region Hovedstaden, Roche Denmark | Patients with metastatic non-clear cell or 100% sarcomatoid renal cell carcinoma referred for first line treatment at the Department of Oncology, Herlev University Hospital Patienter med metastatisk non-clear cell eller 100% sarkomatoid nyrekræft, som henvises med henblik på første linje behandling på onkologisk afdeling, Herlev Hospital, Patients with metastatic kidney cancer with the subtype non-clear cell or 100% sarcomatoid referred for first line treatment at the Department of Oncology, Herlev University Hospital Patienter med undertypen non-clear cell eller 100% sarkomatoid nyrekræft, som har spredt sig og henvises for at påbegynde den første medicinske kræftbehandling på onkologisk afdeling, Herlev Hospital, Diseases [C] - Cancer [C04] | | | | |
2018-004623-36: MEGALiT - a study in which the effect of established cancer drugs is investigated on new cancers that have a specific molecular signature MEGALiT - en studie där effekten av etablerade cancerläkemedel undersöks på nya cancersjukdomar som har en specifik molekylär signatur |
|
|
| Not yet recruiting | 2 | 154 | Europe | Tecentriq, Cotellic, Zejula, Everolimus, RO5514041/F04, Concentrate for solution for infusion, Film-coated tablet, Capsule, hard, Tablet, Tecentriq, Cotellic, Zejula | Uppsala University Hospital, Roche AB | In part 1 of the study: any solid tumor with the exemption of sarcoma. In part 2: any solid tumor or hematological malignancy, In part 1 of the study: any solid tumor with the exemption of sarcoma. In part 2: any solid tumor or hematological malignancy, Diseases [C] - Cancer [C04] | | | | |
2019-002085-13: A Pilot Study of Oraxol in Subjects with Cutaneous Angiosarcoma |
|
|
| Not yet recruiting | 2 | 43 | Europe | Oraxol, HM30181AK-US, paclitaxel capsules, Tablet, Capsule, hard | Athenex, Inc, Athenex, Inc | Study of Oraxol in Subjects with Cutaneous Angiosarcoma, Soft tissue sarcoma, Diseases [C] - Cancer [C04] | | | | |
2018-004104-19: A study to investigate the efficacy and safety of L19TNF in previously treated patients with advanced stage or metastatic soft-tissue sarcoma |
|
|
| Not yet recruiting | 2 | 98 | Europe | Onfekafusp alfa, Dacarbazin, L19TNF, Solution for injection, Powder for solution for injection/infusion, Dacarbazin | Philogen S.p.A., PHILOGEN S.P.A., Philogen S.p.A., | Unresectable and/or metastatic soft-tissue sarcoma after failure of at least two prior systemic therapy regimens, Soft-tissue sarcoma after failure of at least two prior systemic therapy regimens, Diseases [C] - Cancer [C04] | | | | |
2019-000589-39: Study to assess the safety and efficacy of T cell therapy in patients with advanced cancer |
|
|
| Not yet recruiting | 2 | 60 | Europe, RoW | ADP-A2M4, ADP-A2M4, Infusion | Adaptimmune LLC, Adaptimmune LLC | Synovial sarcoma, Myxoid round cell liposarcoma, Soft tissue cancer, Diseases [C] - Cancer [C04] | | | | |
OSTPDL1, NCT03006848: A Phase II Trial of Avelumab in Patients With Recurrent or Progressive Osteosarcoma |
|
|
| Completed | 2 | 19 | US | Avelumab, MSB0010718C, anti-PD-L1, Questionnaires, PROMIS Pediatric Profile, PROMIS Adult Profile | St. Jude Children's Research Hospital, Pfizer, Gateway for Cancer Research | Osteosarcoma | 03/20 | 03/20 | | |
2018-004332-30: Study that evaluating the efficacy of lenvatinib in patients with locally advanced GIST after failure of imatinib and sunitinib Etude évaluant l’efficacité du Lenvatinib chez des patients présentant un GIST localement avancé après échec de l’imatinib et du sunitinib |
|
|
| Not yet recruiting | 2 | 74 | Europe | E7080, Capsule, Lenvima | Centre Léon Bérard, EISAI SAS | Patients with locally advanced or metastatic GIST after failure of imatinib and sunitinib (either on 3rd line treatment or beyond a 3rd line with regorafenib) Patients avec un GIST métastatique ou localement avancé, après échec du traitement par imatinib et sunitinib (en 3ème ligne de traitement ou au-delà d’une 3ème ligne par regorafenib), Patients with metastatic GIST Patients présentant un GIST métastatique, Diseases [C] - Cancer [C04] | | | | |
NCT02923934: A Phase II Trial of Ipilimumab and Nivolumab for the Treatment of Rare Cancers |
|
|
| Active, not recruiting | 2 | 120 | RoW | Ipilimumab, YERVOY ®, Nivolumab, Opdivo | Olivia Newton-John Cancer Research Institute, Bristol-Myers Squibb | Gastrointestinal Cancer, Neuroendocrine Tumours, Malignant Female Reproductive System Neoplasm | 04/20 | 12/23 | | |
|
|
2019-004403-12: Phase II multicenter study of talimogene laherparepvec in classic or endemic Kaposi sarcoma Kapvec Study Essai clinique de phase II multicentrique évaluant le talimogene laherparepvec dans la maladie de Kaposi classique ou endémique |
|
|
| Not yet recruiting | 2 | 20 | Europe | talimogene laherparepvec, Solution for injection, Imlygic | ASSISTANCE PUBLIQUE DES HOPITAUX DE PARIS, Amgen | The study will provide an overview of efficacy and safety of talimogene laherparepvec in classic and endemic KS traitement par T-Vec de patients atteints du Sarcome de Kaposi., Diseases [C] - Cancer [C04] | | | | |
PEMBROSARC, NCT02406781: Combination of MK3475 and Metronomic Cyclophosphamide in Patients With Advanced Sarcomas : Multicentre Phase II Trial |
|
|
| Active, not recruiting | 2 | 227 | Europe | Combination of MK3475 with Metronomic CP, Pembrolizumab, Endoxan, Combination of MK3475 with Metronomic CP and G100, Pembrolizumab, Endoxan, GLA-SE (glucopyranosyl lipid adjuvant-stable emulsion). | Institut Bergonié, Merck Sharp & Dohme LLC, Ministry of Health, France, Immune Design | Sarcoma | 11/20 | 08/21 | | |
NCT04294511: Study of Camrelizumab in Combination With Neoadjuvant Chemotherapy in the Treatment of Osteosarcoma |
|
|
| Recruiting | 2 | 75 | RoW | Camrelizumab in Combination With Neoadjuvant Chemotherapy, PD-1 inhibitor | Sun Yat-sen University, Jiangsu HengRui Medicine Co., Ltd. | Osteosarcoma | 03/21 | 09/23 | | |
NCT04118166: Ipilimumab + Nivolumab + Cryotherapy in Metastatic or Locally Advanced Soft Tissue Sarcoma |
|
|
| Completed | 2 | 30 | US | Ipilimumab, Yervoy, BMS-734016, MDX010, MDX-CTLA4, Cryoablation, Nivolumab, BMS-936558, MDX1106, ONO-4538 | Kristen Ganjoo, Bristol-Myers Squibb | Soft Tissue Sarcoma | 01/22 | 04/22 | | |
2020-000741-13: Trial assessing the activity of TrabectedIn vs gemCitabine in patients with advanced LEiomyosarcoma Studio sull’attività della Trabectedina vs Gemcitabina in pazienti con leiomiosarcoma avanzato pretrattati c |
|
|
| Not yet recruiting | 2 | 100 | Europe | Trabectedina, Gemcitabina, [trabectedina], [Gemcitabina], Powder for infusion, Concentrate for solution for infusion, Yondelis, GEMCITABINA ACCORD - 100 MG/ML CONCENTRATO PER SOLUZIONE PER INFUSIONE 1 FLACONCINO IN VETRO DA 2 ML | ITALIAN SARCOMA GROUP, Pharmamar | metastatic or locally advanced Leiomyosarcoma pretreated with conventional chemotherapy leiomiosarcoma metastatico o localmente avanzato pretrattati con chemioterapia convenzionale, advanced Leiomyosarcoma leiomiosarcoma avanzato, Diseases [C] - Cancer [C04] | | | | |
2020-004426-36: Clinical trial of combined therapy with pembrolizumab and lenvatinib for patients with classic Kaposi sarcoma treated with at least one previous line of chemioterapy. Studio clinico della terapia combinazione di pembrolizumab e lenvatinib nei pazienti con sarcoma di Kaposi classico trattato con una precedente chemioterapia. |
|
|
| Ongoing | 2 | 25 | Europe | Lenvatinib, Keytruda, [E7080/MK7902], [Pembrolizumab], Capsule, hard, Solution for infusion, KEYTRUDA (pembrolizumab, MK3475 | FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO, Merck Sharp & Dohme Corp. | Advanced unresectable classic Kaposi sarcoma relapsed and/or refractory to previous standard treatments. Sarcoma di Kaposi classico stadio avanzato non resecabile, recidivato e/o refrattario a precedenti trattamenti standard., Advanced unresectable classic Kaposi sarcoma, with progression and/or disease relapse during previous chemotherapy. Sarcoma di Kaposi classico avanzato non operabile, che abbia mostrato una progressione e/o una recidiva a una precedente chemioterapia., Diseases [C] - Skin and Connective Tissue Diseases [C17] | | | | |
| Completed | 2 | 6 | Europe | LTX-315 and TILs | Lytix Biopharma AS, Herlev Hospital | Soft Tissue Sarcoma | 07/21 | 10/21 | | |
2020-005703-39: Bintrafusp alfa and Doxorubicin Hydrochloride in Treating Patients With Advanced Sarcoma. Bintrafusp alfa et doxorubicine chez les patients traités pour un sarcome avancé. |
|
|
| Not yet recruiting | 2 | 80 | Europe | Bintrafusp alfa, DOXORUBICIN, M7824, Concentrate for solution for injection/infusion, Solution for infusion, DOXORUBICIN | Institut Bergonié, Merck Healthcare KGaA | soft-tissue sarcoma sarcomes des tissus mous, soft-tissue sarcoma sarcomes des tissus mous, Diseases [C] - Cancer [C04] | | | | |
NCT03623581: Clinical Trial in Chinese Patients of Elapsed/Metastatic/Unresectable Alveolar Soft Part Sarcoma(GB226) |
|
|
| Recruiting | 2 | 35 | RoW | GB226, Recombinant humanized anti-PD-1 monoclonal antibody injection, Geptanolimab | Genor Biopharma Co., Ltd. | Alveolar Soft Part Sarcoma | 08/21 | 12/22 | | |
| Completed | 2 | 15 | Europe | regorafenib, Stivarga | Grupo Espanol de Investigacion en Sarcomas, Bayer | Gastrointestinal Stromal Tumors | 08/21 | 08/21 | | |
2018-003835-31: Targeting ATR in soft-tissue sarcomas: a randomized phase II study. TARSARC study Ciblage d’ATR dans les sarcomes des tissus mous : une étude randomisée de phase II. Etude TARSARC |
|
|
| Not yet recruiting | 2 | 72 | Europe | Berzosertib, GEMCITABINE, M6620, Solution for infusion, GEMCITABINE | Institut Bergonié, Merck Healthcare KGaA | Locally advanced/unresectable and/or metastatic soft-tissue leiomyosarcomas Léiomyosarcomes localement avancés et/ou métastatiques, Locally advanced/unresectable and/or metastatic soft-tissue leiomyosarcomas Léiomyosarcomes localement avancés et/ou métastatiques, Diseases [C] - Cancer [C04] | | | | |
| Recruiting | 2 | 120 | Europe, Canada, US | afamitresgene autoleucel (previously ADP-A2M4) | Adaptimmune | Synovial Sarcoma, Myxoid Liposarcoma | 10/21 | 04/38 | | |
|
|
|
2021-001085-37: Bintrafusp alfa and Doxorubicin Hydrochloride in Treating Patients With Advanced Sarcoma. Chimiothérapie néo-adjuvante plus retifanlimab (INCMGA00012)chez les patients porteurs de sarcomes rétropéritoneaux sélectionnés : une étude randomisée de phase II. |
|
|
| Not yet recruiting | 2 | 66 | Europe | Retifanlimab, DOXORUBICIN, HOLOXAN, INCMGA00012, Solution for infusion, Powder for infusion, DOXORUBICIN, HOLOXAN (Ifosfamide) | Institut Bergonié, Incyte Biosciences International Sarl | retroperitoneal sarcomas sarcomes rétropéritonéaux, retroperitoneal sarcomas sarcomes rétropéritonéaux, Diseases [C] - Cancer [C04] | | | | |
NCT04606108: Study of Camrelizumab in Combination With Neoadjuvant Chemotherapy in the Treatment of High-risk Soft Tissue Sarcoma |
|
|
| Recruiting | 2 | 62 | RoW | Camrelizumab in Combination With Neoadjuvant Chemotherapy, PD-1 inhibitor | Sun Yat-sen University, Jiangsu HengRui Medicine Co., Ltd. | Soft Tissue Sarcoma | 10/21 | 03/24 | | |
| Completed | 2 | 30 | US | Pembrolizumab, KEYTRUDA®, Doxorubicin, Adriamycin | Wake Forest University Health Sciences, Merck Sharp & Dohme LLC | Soft Tissue Sarcoma, Adult, Soft Tissue Sarcoma, Child | 11/21 | 11/22 | | |
MP-VAC-206, NCT06219733: Vactosertib and Imatinib Combination in Patients With Advanced Desmoid Tumor/Aggressive Fibromatosis (DT/AF) |
|
|
| Recruiting | 2 | 76 | RoW | Vactosertib, Imatinib | MedPacto, Inc. | Dermoid | 11/21 | 09/29 | | |
2020-002366-13: Combination of pembrolizumab and cabozantinib in patients with advanced sarcomas Association du Pembrolizumab et du Cabozantinib chez les patients porteurs d’un sarcome avancé |
|
|
| Not yet recruiting | 2 | 119 | Europe | PEMBROLIZUMAB, CABOZANTINIB, MK-3475, XL184, Solution for infusion, Film-coated tablet, KEYTRUDA, CABOMETYX | Institut Bergonié, Groupement Interrégional de Recherche Clinique et d’Innovation Sud-ouest Outre-mer Hospitalier, IPSEN PHARMA | Advanced /metastatic sarcomas: undifferentiated pleomorphic sarcoma, osteosarcoma and Ewing sarcoma Sarcomes localement avancés et/ou métastatiques : sarcomes indifférenciés, ostéosarcomes et sarcomes d’Ewing, Advanced /metastatic sarcomas: undifferentiated pleomorphic sarcoma, osteosarcoma and Ewing sarcoma Sarcomes localement avancés et/ou métastatiques : sarcomes indifférenciés, ostéosarcomes et sarcomes d’Ewing, Diseases [C] - Cancer [C04] | | | | |
NCT02897479: A Phase II Study of HMPL-504 in Lung Sarcomatoid Carcinoma and Other Non-small Cell Lung Cancer |
|
|
| Active, not recruiting | 2 | 76 | RoW | Savolitinib, hmpl-504 | Hutchison Medipharma Limited | Lung Sarcomatoid Carcinoma | 12/21 | 12/21 | | |
UNISoN, NCT03177239: Phase II Sequential Treatment Trial of Single Agent Nivolumab, Then Combination Ipilimumab + Nivolumab in Metastatic or Unresectable Non-Clear Cell Renal Cell Carcinoma (ANZUP1602) |
|
|
| Active, not recruiting | 2 | 85 | RoW | Nivolumab, Opdivo, Ipilimumab, Yervoy | Australian and New Zealand Urogenital and Prostate Cancer Trials Group, Bristol-Myers Squibb | Renal Cell Carcinoma, Papillary Renal Cell Carcinoma Type 1, Papillary Renal Cell Carcinoma Type 2, Chromophobe Renal Cell Carcinoma, Sarcomatoid Renal Cell Carcinoma, Xp11 Translocation Carcinoma | 12/21 | 12/22 | | |
EAGLES, NCT03536780: Avelumab in Combination With Gemcitabine in Advanced Leiomyosarcoma as a Second-line Treatment |
|
|
| Recruiting | 2 | 38 | RoW | Avelumab and Gemcitabine | Gachon University Gil Medical Center, Merck KGaA, Darmstadt, Germany, Chong Kun Dang Pharmaceutical Corp. | Leiomyosarcoma Metastatic | 12/21 | 12/22 | | |
2017-001083-38: Combined treatment with Nivolumab and Trabectedin in patients with metastatic or inoperable soft tissue Sarcomas |
|
|
| Not yet recruiting | 2 | 92 | Europe | Nivolumab, Trabectedin, Concentrate for solution for infusion, Powder for concentrate for solution for infusion, Opdivo®, Yondelis | Universitätsmedizin Greifswald, Bristol-Myers Squibb GmbH und Co. KG, Pharma Mar, S.A. | metastatic or inoperable soft tissue sarcoma metastasiertes oder inoperables Weichteilsarkom, metastatic or inoperable soft tissue sarcoma metastasiertes oder inoperables Weichteilsarkom, Diseases [C] - Cancer [C04] | | | | |
2021-003788-82: A phase 2 on propranolol in combination with pembrolizumab in advanced Angiosarcoma and Undifferentiated Pleomorphic Sarcoma Et fase 2 forsøg af propanolol i kombination med pembrolizumab til patienter med fremskreden angiosarkom eller udifferentieret pleomorf sarkom. |
|
|
| Not yet recruiting | 2 | 80 | Europe | Film-coated tablet, Powder for concentrate for solution for infusion, Concentrate for solution for infusion, Keytruda | Department of Oncology, Herlev & Gentofte Hospital, Nordic Cancer Union | Advanced Angiosarcoma and Undifferentiated Pleomorphic Sarcoma, Two types of advanced soft tissue sarcoma (Angiosarcoma and Undifferentiated Pleomorphic Sarcoma ), Diseases [C] - Cancer [C04] | | | | |
2021-002635-35: A Phase 2 study of INBRX-109 in adults with a type of unresectable or metastasized cancer of the bones and joints (Conventional Chondrosarcoma). Estudio de fase 2, de INBRX-109 en adultos en un tipo de cancer de huesos y articulaciones irresecable o metastasico (condrosarcoma convencional) |
|
|
| Not yet recruiting | 2 | 201 | Europe | Desametasone, Difenidramina, INBRX-109, INBRX-109, Lyophilisate for solution for infusion | Inhibrx, Inc., Inhibrx, INC, Inhibrx, Inc. | Unresectable or metastatic conventional chondrosarcoma condrosarcoma convencional irresecable o metastásico., Malignant bone tumor that cannot be resected or it has been spread from the primary site (place where it started) to other places in the body. Tumor óseo maligno que no puede ser resecado o que se ha extendido desde el sitio primario (lugar donde comenzó) a otros lugares del cuerpo., Diseases [C] - Cancer [C04] | | | | |
NCT04154189 / 2019-003696-19: A Study to Compare the Efficacy and Safety of Ifosfamide and Etoposide With or Without Lenvatinib in Children, Adolescents and Young Adults With Relapsed and Refractory Osteosarcoma |
|
|
| Completed | 2 | 81 | Europe, Canada, US, RoW | Lenvatinib, E7080, Ifosfamide, Etoposide | Eisai Inc., Merck Sharp & Dohme LLC | Osteosarcoma | 06/22 | 08/23 | | |
NCT02879162: Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours |
|
|
| Active, not recruiting | 2 | 140 | Canada | Durvalumab, Tremelimumab | Canadian Cancer Trials Group, AstraZeneca | Advanced Rare Tumours | 06/22 | 12/22 | | |
NCT03331250: Eribulin in Angiosarcoma and Epithelioid Hemangioendothelioma (EHE) |
|
|
| Active, not recruiting | 2 | 13 | US | Eribulin, Halaven | Massachusetts General Hospital, Eisai Inc. | Angiosarcoma, Epithelioid Hemangioendothelioma | 07/22 | 05/25 | | |
NCT03912818: Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder Cancer |
|
|
| Terminated | 2 | 7 | US | Carboplatin, Carboplat, Carboplatino, Carbosol, Paraplatin, Paraplatine, Cisplatin, Abiplatin, Briplatin, Cis-platinum, Cismaplat, Citoplatino, Plastistil, Platinol, Cystectomy, Doxorubicin, Adriablastin, Hydroxyl Daunorubicin, Rubex, Durvalumab, Imfinzi, MEDI-4736, Gemcitabine, Difluorodeoxycytidine, Gemzar, Methotrexate, Abitrexate, Amethopterin, Brimexate, Methotrexate Methylaminopterin, Metotrexato, Vinblastine, Vincaleucoblastine, Vinblastine Sulfate, vincaleukoblastine, sulfate | Stanford University, AstraZeneca | Bladder Adenocarcinoma, Bladder Mixed Adenocarcinoma, Bladder Squamous Cell Carcinoma, Bladder Urothelial Carcinoma, Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant, Infiltrating Bladder Urothelial Carcinoma With Giant Cells, Infiltrating Bladder Urothelial Carcinoma With Glandular Differentiation, Infiltrating Bladder Urothelial Carcinoma With Trophoblastic Differentiation, Infiltrating Bladder Urothelial Carcinoma, Clear Cell Variant, Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant, Infiltrating Bladder Urothelial Carcinoma, Nested Variant, Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant | 08/22 | 08/22 | | |